Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November

Company News

Novan (Nasdaq:NOVN) today announced that enrollment in the Company’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum has fully enrolled all cohorts. As quoted in the press release: The trial was initiated in January of 2018; the Company previously communicated that top line results were …

Novan (Nasdaq:NOVN) today announced that enrollment in the Company’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum has fully enrolled all cohorts.

As quoted in the press release:

The trial was initiated in January of 2018; the Company previously communicated that top line results were targeted to be available in the fourth quarter of 2018. Based on the expedient enrollment, top line results for Cohorts 1 to 3 with SB206 4%, 8% and 12% twice-daily are now targeted to be communicated no later than mid-November, with Cohort 4, SB206 12% once-daily targeted to be reported in December.

“In addition to achieving the positive enrollment milestone, the favorable safety profile of our nitric oxide technology was reaffirmed with no significant safety concerns reported in the trial to date, allowing for escalation to the highest, 12% dose of SB206 for treatment in the trial,” stated Paula Brown Stafford, Novan’s Chief Development Officer. “In this largely pediatric population, a safe and efficacious product would greatly benefit the large majority of patients left untreated due to often painful, commonly-used ablative treatments.”

Click here to read the full press release.

The Conversation (0)
×